Application Of ATP-TCA Assay In The Screening Of Neoadjuvant Chemotherapeutic Agents For Breast Cancer

Objective: The purpose of this research was to investigate the difference in susceptibility treatment group and experience treatment group under the guidance of ATP bioluminescence tumor chemosensitivity assay(ATP-TCA) and evaluate its guiding value in the screening of neoadjuvant chemotherapeutic agents for breast cancer.Methods: 85 samples of pathological diagnosis of Ⅱ,Ⅲ stage breast cancer were randomly divided into two groups. The patients in experience treatment group(n=40) were given the standard program [Paclitaxel(PTX)+ Epirubicin(EPI)];the susceptibility treatment group(n=45) were given in vitro susceptibility test for PTX, EPI, Therarubicin(THP), TT(PTX+ THP), TE(PTX+ EPI),TC(PTX+CTX), CTF(CTX+THP+5-Fu), CEF(CTX+ EPI+5-Fu), the chemotherapy program was selected according to the results of in vitro susceptibility test; and the efficiency was compared between two groups.Results: The appreciation rate is 91.1%.The curative effect of combination is superior to the single drug use because of significant differences in chemosensitivity among individuals. The efficiency(88.9%) of chemotherapy test group according was higher than the efficiency rate(70.0%) of experience treatment group, P<0.05.Conclusion: ATP-TCA technique is an effective method in detecting chemosensitivity, and has important clinical value to guide individualized neoadjuvant chemotherapy for Ⅱ,Ⅲ stage breast cancer.